High-resolution Structures of the Bound Effectors Avadomide (CC-122) and Iberdomide (CC-220) Highlight Advantages and Limitations of the MsCI4 Soaking System

Overview

Journal Acta Crystallogr D Struct Biol

Specialty Biochemistry

Date 2022 Mar 2

PMID 35234143

Authors

Christopher Heim

Marcus D Hartmann

Affiliations

Soon will be listed here.

Abstract

Cereblon (CRBN) is the substrate receptor of the CRL4 E3 ubiquitin ligase and is a central player in targeted protein degradation. It is the target of the thalidomide-derived immunomodulatory drugs (IMiDs) and is one of the most widely employed receptors for proteolysis-targeting chimeras (PROTACs), both of which induce the ubiquitination and subsequent proteasomal degradation of target proteins. Structural studies of ligand binding to CRBN are crucial to elucidate the mechanisms of action and for mediation of side effects, ultimately aiding the development of next-generation IMiDs and PROTACs. With this aim, a crystal-soaking system based on the single-domain bacterial homologue MsCI4 has previously been established and used to delineate the binding modes of several classes of small molecules, including FDA-approved drugs, at the molecular level. Here, this system was used to characterize the binding of the next-generation IMiDs avadomide (CC-122) and iberdomide (CC-220) at high resolution, highlighting the advantages and limitations of the MsCI4 system and its implications for the development of future cereblon effectors.

Citing Articles

-Boc-α-diazo glutarimide as efficient reagent for assembling N-heterocycle-glutarimide diads via Rh(II)-catalyzed N-H insertion reaction.

Kantin G, Golubev P, Sapegin A, Bunev A, Darin D Beilstein J Org Chem. 2023; 19:1841-1848.

PMID: 38090627 PMC: 10714472. DOI: 10.3762/bjoc.19.136.

Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.

Steinebach C, Bricelj A, Murgai A, Sosic I, Bischof L, Ng Y J Med Chem. 2023; 66(21):14513-14543.

PMID: 37902300 PMC: 10641816. DOI: 10.1021/acs.jmedchem.3c00851.

Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design.

Kuchta R, Heim C, Herrmann A, Maiwald S, Ng Y, Sosic I RSC Chem Biol. 2023; 4(3):229-234.

PMID: 36908700 PMC: 9994103. DOI: 10.1039/d2cb00223j.

Molecular glue CELMoD compounds are regulators of cereblon conformation.

Watson E, Novick S, Matyskiela M, Chamberlain P, H de la Pena A, Zhu J Science. 2022; 378(6619):549-553.

PMID: 36378961 PMC: 9714526. DOI: 10.1126/science.add7574.

References

Kale V, List A . Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. Curr Pharm Biotechnol. 2006; 7(5):339-42. DOI: 10.2174/138920106778521587. View

Hagner P, Man H, Fontanillo C, Wang M, Couto S, Breider M . CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015; 126(6):779-89. PMC: 4528065. DOI: 10.1182/blood-2015-02-628669. View

Boichenko I, Deiss S, Bar K, Hartmann M, Hernandez Alvarez B . A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands. J Med Chem. 2016; 59(2):770-4. DOI: 10.1021/acs.jmedchem.5b01735. View

Maiwald S, Heim C, Hernandez Alvarez B, Hartmann M . Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay. ACS Med Chem Lett. 2021; 12(1):74-81. PMC: 7812675. DOI: 10.1021/acsmedchemlett.0c00440. View

Kronke J, Udeshi N, Narla A, Grauman P, Hurst S, McConkey M . Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2013; 343(6168):301-5. PMC: 4077049. DOI: 10.1126/science.1244851. View

Van Nguyen T, Lee J, Sweredoski M, Yang S, Jeon S, Harrison J . Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon. Mol Cell. 2016; 61(6):809-20. PMC: 4889030. DOI: 10.1016/j.molcel.2016.02.032. View

Steinebach C, Sosic I, Lindner S, Bricelj A, Kohl F, Ng Y . A MedChem toolbox for cereblon-directed PROTACs. Medchemcomm. 2019; 10(6):1037-1041. PMC: 6596386. DOI: 10.1039/c9md00185a. View

Matyskiela M, Lu G, Ito T, Pagarigan B, Lu C, Miller K . A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016; 535(7611):252-7. DOI: 10.1038/nature18611. View

Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

10.

Heim C, Maiwald S, Steinebach C, Collins M, Strope J, Chau C . On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. Biochem Biophys Res Commun. 2020; 534:67-72. PMC: 7815984. DOI: 10.1016/j.bbrc.2020.11.117. View

11.

Matyskiela M, Clayton T, Zheng X, Mayne C, Tran E, Carpenter A . Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex. Nat Struct Mol Biol. 2020; 27(4):319-322. DOI: 10.1038/s41594-020-0405-9. View

12.

Chamberlain P, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B . Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014; 21(9):803-9. DOI: 10.1038/nsmb.2874. View

13.

Bricelj A, Steinebach C, Kuchta R, Gutschow M, Sosic I . E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front Chem. 2021; 9:707317. PMC: 8287636. DOI: 10.3389/fchem.2021.707317. View

14.

Lupas A, Zhu H, Korycinski M . The thalidomide-binding domain of cereblon defines the CULT domain family and is a new member of the β-tent fold. PLoS Comput Biol. 2015; 11(1):e1004023. PMC: 4287342. DOI: 10.1371/journal.pcbi.1004023. View

15.

Cruz M . Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma. P T. 2016; 41(5):308-13. PMC: 4849339. View

16.

Nguyen T, Li J, Lu C, Mamrosh J, Lu G, Cathers B . p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc Natl Acad Sci U S A. 2017; 114(14):3565-3571. PMC: 5389304. DOI: 10.1073/pnas.1700949114. View

17.

Fischer E, Bohm K, Lydeard J, Yang H, Stadler M, Cavadini S . Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014; 512(7512):49-53. PMC: 4423819. DOI: 10.1038/nature13527. View

18.

Boichenko I, Bar K, Deiss S, Heim C, Albrecht R, Lupas A . Chemical Ligand Space of Cereblon. ACS Omega. 2019; 3(9):11163-11171. PMC: 6644994. DOI: 10.1021/acsomega.8b00959. View

19.

Murshudov G, Skubak P, Lebedev A, Pannu N, Steiner R, Nicholls R . REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):355-67. PMC: 3069751. DOI: 10.1107/S0907444911001314. View

20.

Steinebach C, Kehm H, Lindner S, Vu L, Kopff S, Lopez Marmol A . PROTAC-mediated crosstalk between E3 ligases. Chem Commun (Camb). 2019; 55(12):1821-1824. DOI: 10.1039/c8cc09541h. View